Date Title Description PDF
23 Feb 2022 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
22 Feb 2022 On buy-back programmes ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022.     Download
16 Feb 2022 On business and financial situation Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years       Download
03 Nov 2021 On buy-back programmes The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. Download
16 Jul 2021 On Corporate Governance ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company   Download

Pages

Date Title Description PDF
10 Apr 2023 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the first quarter of 2023 Download
21 Feb 2023 Annual Corporate Governance Report ROVI releases the 2022 Annual Corporate Governance Report Download
21 Feb 2023 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2022 annual report regarding remuneration of the members of the Board of Directors Download
16 Feb 2023 On business and financial situation The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States. Download
09 Jan 2023 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the fourth quarter of 2022 Download

Pages

Date Title Description PDF
08 Oct 2018 Share capital increases and reductions Information on the registration in the Commercial Registry of Madrid of the notarial deed regarding the capital increase Download
05 Oct 2018 Buy-back programmes, stabilisation and treasury stock Information about the possibility that Jefferies International Limited carries out stabilisation transactions within the framework of the capital increase excluding pre-emptive subscription rights of the existing shareholders of Laboratorios Farmacéuticos Rovi, S.A. Download
04 Oct 2018 Share capital increases and reductions Directors’ Report and Independent Expert Report related to capital increase excluding preferential subscription rights Download
04 Oct 2018 Liquidity contracts and specialists The Company informs that has temporarily suspended liquidity agreement with JB Capital Markets, Sociedad de Valores, S.A.U. Download
04 Oct 2018 Share capital increases and reductions Information on price fixing and outcome of the private placement related to capital increase addressed to institutional investors, excluding preferential subscription rights Download

Pages